首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi

市場調查報告書

商品編碼

1424446

CD55 缺乏症（CHAPLE 症候群）治療藥物的全球市場：按類型、診斷、分銷管道和地區分類

Global Chaple Disease Therapeutics Market, By Type, By Diagnosis, By Distribution Channel, By Geography

出版日期: 2024年01月16日 | 出版商:

Coherent Market Insights | 英文 170 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球 CD55 缺乏症（CHAPLE 症候群）治療市場規模預計將從2024年的 1.453 億美元增加到2031年的 1.576 億美元，年複合成長率（CAGR）1.2%。

報告範圍		報告詳情
基準年	2023年	2023/2024年市場規模	1.453 億美元
實際資料	2019年至2023年	預測期	2024-2031
預測期2023/2024~2030/2031年複合成長率：	1.20%	2030/2031價值預測	1.576 億美元

圖 1.2024年治療 CD55 缺乏症（CHAPLE 症候群）藥物的全球市場佔有率（%），依地區分類

Chapple 症候群，也稱為 DAF 或 CD55 缺乏症，是指自然界中與免疫系統相關的一種罕見遺傳疾病。 CHAPLE 是「血管病變血栓症、CD55 缺乏伴補體高活化和嚴重蛋白質丟失性腸道疾病（PLE）」的縮寫。這種疾病始於兒童時期，可能致命。 CD55 缺乏症（CHAPLE 症候群）治療市場是指可用於治療 Chapple 病的醫療選擇。查普氏症是一種罕見的、慢性的、進行性的神經肌肉疾病，其特徵是肌肉無力和無力。查普氏症無法治療方法，治療的目的是控制症狀和提高生活品質。常見的治療方法包括維持肌肉力量和活動能力的物理治療、緩解疼痛和肌肉痙攣的藥物、插入管子以協助營養和呼吸的手術以及脊椎支撐。有用於此目的的矯正器具和矯正器具。研究人員研究新的藥物和基因療法，這些療法可能在未來減緩疾病的進展。全球 CD55 缺乏症（CHAPLE 症候群）治療市場是由該疾病日益流行以及對有效治療解決方案不斷成長的需求所推動的。

市場動態：

由於開發新藥和基因療法的研究投資增加，患者支持團體提高的疾病意識以及新興國家醫療成本的上升，全球 CD55 缺乏症（CHAPLE 症候群）治療藥物市場預計將成長。時期。然而，開發孤兒藥的高成本和缺乏核准的治療方法可能會限制市場擴張。另一方面，新的基因療法有可能改變治療格局並為市場相關人員提供機會。主要市場參與企業積極與研究機構合作，探索新的標靶和創新的治療策略。

本研究的主要特點

本報告對全球CD55缺乏症（CHAPLE症候群）治療藥物市場進行了詳細分析，並提出了以2023年為基準年的預測期（2024-2031年）的市場規模和年複合成長率（CAGR%）。
揭示了各個細分市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
主要公司概況包括Alexion Pharmaceuticals Inc.、Akari Therapeutics、Apellis Pharmaceuticals、Amgen Inc.、CinnaGen Co.、Novartis AG、F. Hoffmann-La Roche Ltd.、Regeneron Pharmaceuticals Inc. 和Alnylam Pharmaceuticals, Inc.。
本報告的見解將使行銷人員和公司負責人能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球 CD55 缺乏症（CHAPLE 症候群）治療市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球肩胛骨疾病治療藥物市場的各種策略矩陣，將促進相關人員的決策。

北美洲
美國
加拿大
歐洲
德國
英國
西班牙
法國
義大利
俄羅斯
其他歐洲國家
亞太地區
中國
印度
日本
澳洲
韓國
ASEAN
其他亞太地區
拉丁美洲
巴西
阿根廷
墨西哥
其他拉丁美洲
中東
海灣合作理事會國家
以色列
其他中東地區
非洲
北非
中部非洲
南非

第9章競爭形勢

公司簡介
- Alexion Pharmaceuticals Inc.
- Akari Therapeutics
- Apellis Pharmaceuticals
- Amgen Inc.
- CinnaGen Co.
- Novartis AG
- Hoffmann-La Roche Ltd
- Regeneron Pharmaceuticals Inc.
- Alnylam Pharmaceuticals, Inc.

第10章

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI6560

Global chaple disease therapeutics market size is expected to reach US$ 157.6 Mn by 2031 from US$ 145.3 Mn in 2024, exhibiting a compound annual growth rate (CAGR) of 1.2% during the forecast period.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 145.3 Mn
Historical Data for:	2019 to 2023	Forecast Period:	2024-2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	1.20%	2030/2031 Value Projection:	US$ 157.6 Mn

Figure 1. Global Chaple Disease Therapeutics Market Share (%), By Region, 2024

Global Chaple Disease Therapeutics Market - IMG1

Chaple syndrome is also known as DAF or CD55 deficiency, which refers to a genetic disorder that is rare in nature and is related to the immune system. CHAPLE is an abbreviated form for 'CD55 deficiency with hyperactivation of angiopathic thrombosis, complement and severe protein-losing enteropathy (PLE)'. This disorder can be seen from childhood and could be fatal to the person. Chaple disease therapeutics market refers to the medical treatment options that are available for managing chaple disease. Chaple disease is a rare, chronic, and progressive neuromuscular disorder characterized by wasting and weakness of muscles. There is no cure for chaple disease and treatment aims to manage symptoms and improve quality of life. Some of the common treatment options include physical therapy to maintain strength and mobility, medications to relieve pain and muscle spasms, surgeries to insert tubes for delivering nutrition or breathing assistance, and bracing or adaptive devices to provide spinal support. Researchers are investigating new drug therapies and gene therapies which may slow the progression of disease in future. Global chaple disease therapeutics market is driven by growing prevalence of the disorder and rising demand for effective therapeutic solutions.

Market Dynamics:

Global chaple disease therapeutics market is expected witness steady growth during the forecast period due to increasing research investments for developing novel drugs and gene therapies, growing disease awareness through patient support organizations, and rising healthcare expenditures in developing nations. However, high costs that are associated with orphan drug development and lack of approved cure are likely to restrain market expansion. Meanwhile, emerging gene therapy approaches hold potential to alter the treatment landscape and provide opportunities for market players. Key market players are actively collaborating with research institutes to explore new targets and innovative treatment strategies.

Key features of the study:

This report provides in-depth analysis of the global chaple disease therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chaple disease therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies - Key companies covered as a part of this study include Alexion Pharmaceuticals Inc., Akari Therapeutics, Apellis Pharmaceuticals, Amgen Inc., CinnaGen Co., Novartis AG, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., and Alnylam Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global chaple disease therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chaple disease therapeutics market

Detailed Segmentation:

Global Chaple Disease Therapeutics Market, By Type
- Eculizumab
- Ravulizumab
- Veopoz
Global Chaple Disease Therapeutics Market, By Diagnosis
- Gastrointestinal Symptoms
- Edema
- Hypoalbuminemia
- Hypogammaglobulinemia
- Malnutrition
Global Chaple Disease Therapeutics Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Global Chaple Disease Therapeutics Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Top Companies in the Global Chaple Disease Therapeutics Market:
- Alexion Pharmaceuticals Inc.
- Akari Therapeutics
- Apellis Pharmaceuticals
- Amgen Inc.
- CinnaGen Co.
- Novartis AG
- Hoffmann-La Roche Ltd
- Regeneron Pharmaceuticals Inc.
- Alnylam Pharmaceuticals, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Type
- Market Snippet, By Diagnosis
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing partnerships among key market players
- Long approval timelines
- Rising healthcare expenditure
Key Highlights
Regulatory Scenario
Market Trends
PEST Analysis
PORTER's Analysis
Product Launches
Mergers, Acquisitions, and Collaborations

4. Global Chaple Disease Therapeutics Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Chaple Disease Therapeutics Market, By Type, 2019-2031, (US$ Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Eculizumab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Ravulizumab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Veopoz
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

6. Global Chaple Disease Therapeutics Market, By Diagnosis, 2019-2031, (US$ Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Gastrointestinal Symptoms
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Edema
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Hypoalbuminemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Hypogammaglobulinemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Malnutrition
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

7. Global Chaple Disease Therapeutics Market, By Distribution Channel, 2019-2031, (US$ Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

8. Global Chaple Disease Therapeutics Market, By Region, 2019-2031, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020 -2031
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
Brazil
Argentina
Mexico
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
GCC Countries
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031,(US$ Mn)
North Africa
Central Africa
South Africa